Document Detail


Intravascular ultrasound findings in ENDEAVOR II and ENDEAVOR III.
MedLine Citation:
PMID:  17950835     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The results of 2 randomized controlled trials of the Endeavor zotarolimus-eluting stent (ZES; Medtronic Vascular, Santa Rosa, CA) were recently reported: ENDEAVOR II, in which the Endeavor stent was compared with the Driver bare metal stent (BMS; Medtronic Vascular), and ENDEAVOR III, in which the Endeavor stent was compared with the first-generation Cypher sirolimus-eluting stent (SES; Cordis Corporation, Miami Lakes, FL). To examine in detail the vascular responses to the Endeavor stent, serial intravascular ultrasound (IVUS) analyses were performed in subsets of patients in the 2 trials at baseline and 8-month follow-up. The investigators report results for various IVUS parameters and compare those with published results for the first-generation SES and paclitaxel-eluting stent (PES). The ZES demonstrated significantly improved effectiveness and equivalent safety compared with the BMS in ENDEAVOR II. Although the ZES seems to be slightly less effective at inhibiting intimal hyperplasia than the SES and PES, early results are indicative of an acceptable safety profile. This finding may be due in part to the relatively complete and uniform neointimal coverage associated with the ZES.
Authors:
Ryota Sakurai; Heidi N Bonneau; Yasuhiro Honda; Peter J Fitzgerald
Related Documents :
11696295 - Update on in-stent restenosis.
11153775 - Arterial remodeling influences the development of intimal hyperplasia after stent impla...
12622445 - Exacerbation of lambert-eaton myasthenic syndrome caused by an l-type ca2+ channel anta...
19543785 - Reduction of neointimal hyperplasia in porcine coronary arteries by 2-deoxy-d-glucose.
2185435 - Colour doppler imaging of arteriovenous malformation of the vein of galen in a newborn.
21654535 - History of the vertebral venous plexus and the significant contributions of breschet an...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  The American journal of cardiology     Volume:  100     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-10-22     Completed Date:  2007-12-06     Revised Date:  2008-06-05    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  71M-76M     Citation Subset:  AIM; IM    
Affiliation:
Center for Cardiovascular Technology, Stanford University Medical Center, Stanford, California 94305-5637, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Bacterial Agents / administration & dosage,  therapeutic use*
Coronary Disease / drug therapy*
Double-Blind Method
Drug-Eluting Stents*
Female
Follow-Up Studies
Humans
Hyperplasia
Male
Middle Aged
Sirolimus / administration & dosage,  analogs & derivatives*,  therapeutic use
Tunica Intima / drug effects,  pathology*,  ultrasonography
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/zotarolimus; 53123-88-9/Sirolimus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The relation between clinical features, angiographic findings, and the target lesion revascularizati...
Next Document:  Real-world safety and efficacy of the endeavor zotarolimus-eluting stent: early data from the E-Five...